Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 3,320 shares of the firm’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $180.55, for a total value of $599,426.00. Following the completion of the sale, the director now directly owns 519,176 shares of the company’s stock, valued at $93,737,226.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Illumina, Inc. (NASDAQ:ILMN) traded up 0.72% during midday trading on Tuesday, hitting $177.87. The stock had a trading volume of 368,034 shares. Illumina, Inc. has a one year low of $119.37 and a one year high of $189.48. The company has a market cap of $25.97 billion, a P/E ratio of 36.00 and a beta of 0.76. The stock has a 50 day moving average of $178.79 and a 200-day moving average of $163.12.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The business had revenue of $598 million for the quarter, compared to the consensus estimate of $590.51 million. During the same period last year, the business earned $0.71 earnings per share. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. Analysts forecast that Illumina, Inc. will post $3.63 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2017/06/20/illumina-inc-ilmn-director-jay-t-flatley-sells-3320-shares-updated-updated.html.
A number of analysts have issued reports on ILMN shares. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $187.00 target price (up from $170.00) on shares of Illumina in a research note on Friday, April 14th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $191.00 price target for the company in a report on Tuesday, April 4th. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $187.82 price target for the company in a report on Monday, March 20th. Cantor Fitzgerald increased their price target on Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a report on Wednesday, April 26th. Finally, Leerink Swann reiterated a “buy” rating on shares of Illumina in a report on Wednesday, April 5th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $165.02.
A number of large investors have recently added to or reduced their stakes in ILMN. Perigon Wealth Management LLC increased its stake in Illumina by 3.9% in the first quarter. Perigon Wealth Management LLC now owns 8,746 shares of the life sciences company’s stock worth $1,492,000 after buying an additional 328 shares during the period. Patten Group Inc. increased its stake in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the period. Piedmont Investment Advisors LLC increased its stake in Illumina by 787.9% in the first quarter. Piedmont Investment Advisors LLC now owns 3,667 shares of the life sciences company’s stock worth $626,000 after buying an additional 3,254 shares during the period. Achmea Investment Management B.V. bought a new stake in Illumina during the first quarter worth $700,000. Finally, Bank of Nova Scotia increased its stake in Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock worth $14,710,000 after buying an additional 62,612 shares during the last quarter. 96.85% of the stock is currently owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.